This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

A Complex DiseaseBCMA as a TargetHealth Disparities in MMResources
The impact of disparities in multiple myeloma (MM) careThe impact of disparities in multiple myeloma (MM) care

While there have been significant advancements in the treatment of MM over the past decade, disparities in care still exist for certain demographic groups.1

MM primarily affects the elderly and disproportionately affects certain racial minorities of all ages. Whether due to age or race, location, income, or a combination of these factors, some people are still not getting the care they need.1

Older patients may be less likely to receive treatment in a timely manner2

While MM is 2X more likely to develop in the Black population vs the White population, improvements in outcomes for Black patients are lagging far behind3

Overall survival for MM patients is ~40% lower for those living in rural areas vs urban areas4

Patients with lower income or those who are uninsured or underinsured have a worse overall survival rate than those with higher incomes and private insurance5-8

It’s important to remember that these factors can be interwoven in complex ways. Open communication with patients, where they can express their concerns, is key.It’s important to remember that these factors can be interwoven in complex ways. Open communication with patients, where they can express their concerns, is key. Disparities in MM care

Listen to a short discussion on disparities in MM care

 Listen LoadingReferences:Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A. Equal treatment and outcomes for everyone with multiple myeloma: are we there yet? Curr Hematol Malig Rep. 2017;12:309-316. doi:10.1007/s11899-017-0393-yFakhri B, Fiala MA, Tuchman SA, Wildes TM. Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies. Clin Lymphoma Myeloma Leuk. 2018;18:219-224. doi:10.1016/j.clml.2018.01.005Marinac CR, Ghobrial IM, Birmann BM, Soiffer J, Rebbeck TR. Dissecting racial disparities in multiple myeloma. Blood Cancer J. 2020;10:19. doi:10.1038/s41408-020-0284-7Elsayed AG, Adler W, Lebowicz Y. Multiple myeloma survival in a rural population. Biomed J Sci Tech Res. 2017;1:579-585. doi:10.26717/BJSTR.2017.01.000249Castañeda-Avila MA, Jesdale BM, Beccia A, Bey GS, Epstein MM. Differences in survival among multiple myeloma patients in the United States SEER population by neighborhood socioeconomic status and race/ethnicity. Cancer Causes Control. 2021;32:1021-1028. doi:10.1007/s10552-021-01454-wCosta LJ, Brill IK, Brown EE. Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States. Cancer. 2016;122:31833190.doi:10.1002/cncr.30183Intzes S, Symeonidou M, Zagoridis K, et al. Socioeconomic status is globally a prognostic factor for overall survival of multiple myeloma patients: synthesis of studies and review of the literature. Mediterr J Hematol Infect Dis. 2021;13:e2021006. doi:10.4084/MJHID.2021.006Fiala MA, Finney JD, Liu J, et al. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma. 2015;56:2643-2649. doi:10.3109/10428194.2015.1011156 Disparities in MM care

Listen to a short discussion on disparities in MM care

 Listen Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-L1A-USA-0137
You are now leaving Pfizer ProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.